Inspection·November 18, 2025

F 0755 Level of Harm - Minimal harm or potential for actual harm Residents Affected - Few Provide pharmaceutical services to meet the needs of each resident and employ or obtain the services of a licensed pharmacist. Based on observation, interview and record review, the facility failed to ensure two out of 17 residents (Resident 10 and Resident 12) had an order from the physician allowing the administration of medications listed as allergies in the residents' medical records. This failure had the potential to create adverse outcomes for the affected residents.Findings:1. During a review of Resident 10's Facesheet dated 9/25/25, document indicated, Resident 10 had an allergy to the medication Atorvastatin (medication used to lower cholesterol in the blood).During a review of Resident 10's Medication Review Report dated 6/1/24-6/30/24 indicated, an order for the medication Atorvastatin Calcium Oral Tablet 20 MG [milligram] (Atorvastatin Calcium) to give 20 mg by mouth one time a day for hyperlipidemia [elevated blood fats including cholesterol] Start Date 6/1/24.During a review of Resident 10's Medication Administration Record (MAR) dated 6/1/24-6/30/24 indicated, Resident 10 was administered Atorvastatin each day for a total of 30 administrations at 2000 (8 p.m.) from 6/1/24-6/30/24.During a review of Resident 10's MAR dated 7/1/24-7/31/24 indicated, Resident 10 was administered Atorvastatin each day for a total of 31 administrations at 2000 from 7/1/24 to 7/31/24.During a review of Resident 10's Medication Review Report dated 10/1/24-10/31/24 indicated, an order for the medication Atorvastatin Calcium Oral Tablet 20 MG [milligram] (Atorvastatin Calcium) to give one tablet by mouth at bedtime related to hyperlipidemia . Start Date 10/6/24.During a review of Resident 10's MAR dated 10/6/24-10/31/24 indicated, Resident 10 was administered Atorvastatin each day for a total of 25 administrations at 2000 from 10/6/24 to 10/31/24.During an interview on 9/25/25, at 1:08 p.m. with Consultant Pharmacist (CP), CP stated Resident 10 had a listed allergy and she should have not receive Atorvastatin. There should have been a note from the physician that Atorvastatin was okay to give.During a review of Resident 10's Medical Record, Record indicated, no note from physician or staff to indicate Atorvastatin was okay to give prior to 6/1/24.During an interview on 9/26/25, at 10:54 a.m., with the Director of Nursing (DON) DON stated Resident 10 received Atorvastatin in June, July and October. DON stated, Resident 10 should have not be given a medication with a listed allergy. 2. During a review of Resident 12's Facesheet dated 9/24/25, document indicated, Resident 12 had an allergy to Acetaminophen (medication used for pain relief or fever reduction).During a review of Resident 12's Medication Review Report, dated 6/19/24 indicated, Resident 12 had an order for Acetaminophen Oral Tablet 325 MG (Acetaminophen) to give two tablets by mouth every 4 hours as needed for mild pain or temp > [greater than] 100 [degrees Fahrenheit] . Start Date 6/19/24.During a review of Resident 12's MAR dated 7/1/25-7/31/25 MAR indicated, Resident was administered Acetaminophen on 7/25/25 at 1557 (3:57 p.m.).During an interview on 9/25/25, at 1:08 p.m. with Consultant Pharmacist (CP) CP stated Resident 12 had a listed allergy and should have not receive that medication. There should have been a note from the physician that the medication was okay to give.During a review of Resident 12's Medical Record, Record indicated, no note from physician or staff to indicate Acetaminophen was okay to give prior to 7/25/25.During an interview on 9/26/25 with DON at (continued on next page) Any deficiency statement ending with an asterisk (*) denotes a deficiency which the institution may be excused from correcting providing it is determined that other safeguards provide sufficient protection to the patients. (See instructions.) Except for nursing homes, the findings stated above are disclosable 90 days following the date of survey whether or not a plan of correction is provided. For nursing homes, the above findings and plans of correction are disclosable 14 days following the date these documents are made available to the facility. If deficiencies are cited, an approved plan of correction is requisite to continued program participation. LABORATORY DIRECTOR'S OR PROVIDER/SUPPLIER REPRESENTATIVE'S SIGNATURE TITLE (X6) DATE FORM CMS-2567 (02/99) Previous Versions Obsolete Facility ID: If continuation sheet Page 1 of 7 Event ID: 056178 Printed: 05/15/2026 Form Approved OMB No. 0938-0391 Department of Health & Human Services Centers for Medicare & Medicaid Services STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION (X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER: (X2) MULTIPLE CONSTRUCTION 056178 B. Wing A. Building (X3) DATE SURVEY COMPLETED 11/18/2025 NAME OF PROVIDER OR SUPPLIER STREET ADDRESS, CITY, STATE, ZIP CODE Manresa Healthcare Center 919 Freedom Blvd Watsonville, CA 95076 For information on the nursing home's plan to correct this deficiency, please contact the nursing home or the state survey agency. (X4) ID PREFIX TAG SUMMARY STATEMENT OF DEFICIENCIES (Each deficiency must be preceded by full regulatory or LSC identifying information)